113 related articles for article (PubMed ID: 27320901)
1. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa-infected patients.
Judd WR; Ratliff PD; Hickson RP; Stephens DM; Kennedy CA
Am J Infect Control; 2016 Nov; 44(11):1275-1279. PubMed ID: 27320901
[TBL] [Abstract][Full Text] [Related]
2. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa.
Eagye KJ; Kuti JL; Nicolau DP
Infect Control Hosp Epidemiol; 2009 Aug; 30(8):746-52. PubMed ID: 19583513
[TBL] [Abstract][Full Text] [Related]
3. The impact of carbapenem-resistant Pseudomonas aeruginosa on clinical and economic outcomes in a Chinese tertiary care hospital: A propensity score-matched analysis.
Chen Z; Xu Z; Wu H; Chen L; Gao S; Chen Y
Am J Infect Control; 2019 Jun; 47(6):677-682. PubMed ID: 30554879
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
5. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes.
Lautenbach E; Synnestvedt M; Weiner MG; Bilker WB; Vo L; Schein J; Kim M
Infect Control Hosp Epidemiol; 2010 Jan; 31(1):47-53. PubMed ID: 19951202
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
McCracken M; Mataseje LF; Loo V; Walkty A; Adam HJ; Hoban DJ; Zhanel GG; Mulvey MR;
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional Analysis of MexAB-OprM Efflux Pumps System of Pseudomonas aeruginosa and Its Role in Carbapenem Resistance in a Tertiary Referral Hospital in India.
Choudhury D; Das Talukdar A; Dutta Choudhury M; Maurya AP; Paul D; Dhar Chanda D; Chakravorty A; Bhattacharjee A
PLoS One; 2015; 10(7):e0133842. PubMed ID: 26221722
[TBL] [Abstract][Full Text] [Related]
8. Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: Prevalence, risk factors, and impact on outcome of infections.
Lin KY; Lauderdale TL; Wang JT; Chang SC
J Microbiol Immunol Infect; 2016 Feb; 49(1):52-9. PubMed ID: 24662016
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality.
Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Macas A; Sakalauskas R
Medicina (Kaunas); 2010; 46(7):490-5. PubMed ID: 20966623
[TBL] [Abstract][Full Text] [Related]
10. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia.
Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Peterson LE; Musser JM
J Infect; 2014 Sep; 69(3):216-25. PubMed ID: 24841135
[TBL] [Abstract][Full Text] [Related]
11. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing.
Tam VH; Ledesma KR; Schilling AN; Lim TP; Yuan Z; Ghose R; Lewis RE
Diagn Microbiol Infect Dis; 2009 Aug; 64(4):427-33. PubMed ID: 19631096
[TBL] [Abstract][Full Text] [Related]
12. Distribution of Pseudomonas-Derived Cephalosporinase and Metallo-β-Lactamases in Carbapenem-Resistant Pseudomonas aeruginosa Isolates from Korea.
Cho HH; Kwon GC; Kim S; Koo SH
J Microbiol Biotechnol; 2015 Jul; 25(7):1154-62. PubMed ID: 25907063
[TBL] [Abstract][Full Text] [Related]
13. Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes.
Lautenbach E; Weiner MG; Nachamkin I; Bilker WB; Sheridan A; Fishman NO
Infect Control Hosp Epidemiol; 2006 Sep; 27(9):893-900. PubMed ID: 16941312
[TBL] [Abstract][Full Text] [Related]
14. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors Associated With Carbapenem-Resistant
Patel K; Kram JJ; Baumgardner DJ
WMJ; 2017 Dec; 116(5):210-214. PubMed ID: 29357210
[TBL] [Abstract][Full Text] [Related]
16. Direct determination of carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa from positive blood cultures using laser scattering technology.
Idelevich EA; Hoy M; Knaack D; Görlich D; Peters G; Borowski M; Becker K
Int J Antimicrob Agents; 2018 Feb; 51(2):221-226. PubMed ID: 29111432
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and risk factors for mortality in cefepime-resistant Pseudomonas aeruginosa bacteremia.
Su TY; Ye JJ; Hsu PC; Wu HF; Chia JH; Lee MH
J Microbiol Immunol Infect; 2015 Apr; 48(2):175-82. PubMed ID: 24064286
[TBL] [Abstract][Full Text] [Related]
18. Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States.
Tabak YP; Merchant S; Ye G; Vankeepuram L; Gupta V; Kurtz SG; Puzniak LA
J Hosp Infect; 2019 Oct; 103(2):134-141. PubMed ID: 31228511
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa.
Oshima K; Nakamura S; Iwanaga N; Takemoto K; Miyazaki T; Yanagihara K; Miyazaki Y; Mukae H; Kohno S; Izumikawa K
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799201
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for hospital-acquired bacteremia due to carbapenem-resistant Pseudomonas aeruginosa in a Colombian hospital.
Valderrama SL; González PF; Caro MA; Ardila N; Ariza B; Gil F; Álvarez C
Biomedica; 2016 Feb; 36(0):69-77. PubMed ID: 27622627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
